Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page ' X2 o# m% \7 \* Z1 R
8 k! [# c3 m3 Q X; ^# t
) V* w: }- W* w* x7 _" d1 wSub-category:- R- X6 \' O" l5 r
Molecular Targets
( h+ V! H9 E# h0 j; b G, q ]% A: N' V! u/ G2 ^1 c" A
, ]( [) m* F$ N% {, ^0 m" p
Category:
8 B1 _$ @5 A* a8 l: x2 \ WTumor Biology
. r8 u9 c) U' T4 m1 G
& [4 u' y: C# c# X) @) _ f3 Z' f& N. w0 p- T6 E; Z2 ?8 }
Meeting:
' N! N F, K9 L2 k, S" c! R2011 ASCO Annual Meeting ) |8 r" K' h; C6 t& ]7 `" `9 j
6 [& D, e8 s: W4 `9 l' ?# a
3 U; `4 k, N! {$ d% @3 C
Session Type and Session Title:
5 [6 J0 B5 g# A! w4 q% APoster Discussion Session, Tumor Biology
, ~ [* \" P! A" U! Q/ S
4 b( e( |0 B1 B4 X1 _5 l# D. q( T- E% `/ e. Q5 @6 f# @
Abstract No:0 c* O; A+ ~6 Q% \5 X
10517 " n/ [( Y& I4 Z1 i$ W* y# O4 x
5 @: u2 v# S" n8 s( B. D% n
' u# G# R z6 K6 P/ H7 L
Citation:3 @' D; I% t: D0 H# O
J Clin Oncol 29: 2011 (suppl; abstr 10517) / l& o8 J6 D; e$ O. l; D
w+ y/ G% ^( r0 O1 d
) s# t2 Y u) J) ^Author(s):. j( e6 ]3 [, k$ o0 Q5 y
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
6 _, h4 m5 k0 w( i
' I" k$ d! E+ m8 k- v: i8 u
0 W2 |+ y9 W) K! {8 S" M: S- a/ O S8 j9 `4 j1 n M/ ^5 B
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.3 y) ^2 M& r7 C$ S% l. R2 G4 P0 h4 B
% S6 W! M6 a; c# {& Q6 G
Abstract Disclosures
( v* z7 B9 ^/ d" C8 _7 p R9 g0 l& z8 ^
Abstract:
' h2 N9 X/ U$ P1 z. N& l' F8 Y1 |) i, \. l4 U' [- l
$ S* s9 a( {, k5 l; @
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.3 ]+ _ h& G- R! R! u4 }9 r# ?1 J
, [# x. ~0 Q1 t: A$ ^& A( r: J
# f9 s0 y* B9 _) z2 b! E |